HK Stock Market Move | CANSINOBIO (06185) has risen over 35%. Institutions point out that the company's development route and antigen design are roughly similar to those of Moderna.

On the news front, CANSINOBIO (06185) saw its stock rise over 60% in early trading, and the gains narrowed in the afternoon. As of the time of writing, it has increased by 35.82%, reaching HKD 31.7, with a transaction volume of HKD 1.368 billion. On August 19, Moderna and Merck announced that their jointly developed melanoma mRNA cancer vaccine reached its primary endpoint in a Phase III clinical trial, making it the first mRNA therapeutic cancer vaccine to be clinically validated globally, confirming the feasibility and commercial value of mRNA technology for cancer treatment. Citi released a research report stating that since Moderna is conducting clinical studies on the same platform for lung cancer, kidney cancer, and bladder cancer, this success represents a platform-level valuation reassessment. CANSINOBIO is positioned on the same technological path, currently having its rhabdomyosarcoma project in the investigator-initiated trial (IIT) phase, while the glioma project is still awaiting preclinical approval. The groups development route and antigen design are roughly similar to Moderna's, with the main difference being its three-component lipid nanoparticle (LNP) system, which is safer than traditional formulations and may support a stronger cellular immune response.